BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36752954)

  • 1. Prognostic value of 18F-FDG lesion dissemination features in patients with peripheral T-cell lymphoma (PTCL).
    Xie Y; Teng Y; Jiang C; Ding C; Zhou Z
    Jpn J Radiol; 2023 Jul; 41(7):777-786. PubMed ID: 36752954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Values of Baseline
    Zhou Y; Zhang X; Qin H; Zhao Z; Li J; Zhang B; Sang S; Wu Y; Deng S
    Biomed Res Int; 2020; 2020():9746716. PubMed ID: 32185229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [
    Xu HQ; Song LJ; Ding CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1690-1700. PubMed ID: 38071047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of metabolic tumour volume on baseline
    Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of pre-treatment and mid-treatment 18F-FDG PET/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS).
    Zhang Y; Wang G; Zhao X; Hu Y; Tan Su Yin E; Chen D; Wang H; Zhao K
    BMC Med Imaging; 2021 Oct; 21(1):145. PubMed ID: 34627196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma.
    Feng X; Wen X; Li L; Sun Z; Li X; Zhang L; Wu J; Fu X; Wang X; Yu H; Ma X; Zhang X; Xie X; Han X; Zhang M
    Cancer Res Treat; 2021 Jul; 53(3):837-846. PubMed ID: 33285054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL).
    Cottereau AS; Becker S; Broussais F; Casasnovas O; Kanoun S; Roques M; Charrier N; Bertrand S; Delarue R; Bonnet C; Hustinx R; Gaulard P; de Leval L; Vera P; Itti E; Mounier N; Haioun C; Tilly H; Meignan M
    Ann Oncol; 2016 Apr; 27(4):719-24. PubMed ID: 26787236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline total metabolic tumor volume combined with international peripheral T-cell lymphoma project may improve prognostic stratification for patients with peripheral T-cell lymphoma (PTCL).
    Jiang C; Teng Y; Chen J; Wang Z; Zhou Z; Ding C; Xu J
    EJNMMI Res; 2020 Sep; 10(1):110. PubMed ID: 32965554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of Baseline and Interim Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT in Patients with Follicular Lymphoma.
    Liang JH; Zhang YP; Xia J; Ding CY; Wu W; Wang L; Cao L; Zhu HY; Fan L; Li TN; Li JY; Xu W
    Cancer Res Treat; 2019 Oct; 51(4):1479-1487. PubMed ID: 30913868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic tumor burden on baseline
    Chen S; He K; Feng F; Wang S; Yin Y; Fu H; Wang H
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1830-1839. PubMed ID: 31187163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of baseline
    Zhou Y; Hong Z; Zhou M; Sang S; Zhang B; Li J; Li Q; Wu Y; Deng S
    J Med Imaging Radiat Oncol; 2020 Feb; 64(1):87-95. PubMed ID: 31880103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline total lesion glycolysis combined with interim positron emission tomography-computed tomography is a robust predictor of outcome in patients with peripheral T-cell lymphoma.
    Kitadate A; Narita K; Fukumoto K; Terao T; Tsushima T; Kobayashi H; Abe Y; Miura D; Takeuchi M; Machida Y; Matsue K
    Cancer Med; 2020 Aug; 9(15):5509-5518. PubMed ID: 32558387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Significance Of Sequential 18f-fdg Pet/Ct During Frontline Treatment Of Peripheral T Cell Lymphomas.
    Song GY; Jung SH; Ahn SY; Kim M; Ahn JS; Lee JJ; Kim HJ; Moon JB; Yoo SW; Kwon SY; Min JJ; Bom HS; Kang SR; Yang DH
    Korean J Intern Med; 2024 Mar; 39(2):327-337. PubMed ID: 38268194
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Girum KB; Rebaud L; Cottereau AS; Meignan M; Clerc J; Vercellino L; Casasnovas O; Morschhauser F; Thieblemont C; Buvat I
    J Nucl Med; 2022 Dec; 63(12):1925-1932. PubMed ID: 35710733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and Prognostic Value of Using 18F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Peripheral T-Cell Lymphoma.
    Abe Y; Kitadate A; Usui Y; Narita K; Kobayashi H; Miura D; Takeuchi M; Oʼuchi E; Oʼuchi T; Matsue K
    Clin Nucl Med; 2019 May; 44(5):e336-e341. PubMed ID: 30889000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of
    Geng H; Lian K; Zhang W
    Quant Imaging Med Surg; 2024 Jan; 14(1):325-334. PubMed ID: 38223089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
    Wu LL; Liang JH; Wang L; Xu W; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
    [No Abstract]   [Full Text] [Related]  

  • 18. Pre-treatment [
    Chen J; Zhao Y
    Hematology; 2024 Dec; 29(1):2325317. PubMed ID: 38465661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG PET/CT Maximum Tumor Dissemination to Predict Recurrence in Patients with Diffuse Large B-Cell Lymphoma.
    Jo JH; Chung HW; Kim SY; Lee MH; So Y
    Nucl Med Mol Imaging; 2023 Feb; 57(1):26-33. PubMed ID: 36643943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of PET-CT for Evaluation of Patients With Peripheral T-cell Lymphoma.
    Gurion R; Bernstine H; Domachevsky L; Michelson C; Raanani P; Vidal L; Shochat T; Gafter-Gvili A
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):687-691. PubMed ID: 30017596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.